Abstract
手术、放射性碘及促甲状腺激素抑制治疗等常规疗法对低分化及未分化甲状腺肿瘤疗效不佳.组蛋白去乙酰化酶(HDAC)作为调控基因转录的关键蛋白酶,其功能异常与肿瘤的发生、发展密切相关.过氧化物酶体增殖物活化受体(PPAR)γ属于激素核受体超家族之一,与细胞的生长、分化密切相关.近来发现HDAC抑制剂及PPARγ激动剂可通过抑制肿瘤细胞增殖、促进其凋亡、诱导其再分化治疗血液系统肿瘤及包括甲状腺肿瘤在内的多种实体瘤,为低分化及未分化甲状腺肿瘤的治疗提供了新思路。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
